The challenge for pharmaceutical commercialisation no longer ends with regulatory approval; it intensifies after the approval. Today there is greater awareness about the benefit and risk of products, not only among healthcare professionals (HCPs), but also among consumers and the payers. Chitra Lele, Chief Scientific Officer at Sciformix Corporation, shares her thoughts about the need for patient-reported outcomes, and their growing prominence, by submitting a white paper on considerations for measurement, analysis and interpretation of data.

[su_document url=”https://international-pharma.com/wp-content/uploads/2015/04/03.-The-Growing-Prominence-and-Need.pdf” height=”980″ responsive=”no”]